BackAnaptysBio Overview

AnaptysBio Receivables

Track AnaptysBio's receivables ($26M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$25.75M
43.97% YoYΔ $7.86M vs prior year quarter

Peer trimmed avg / median

Loading

AnaptysBio Receivables History

Loading

AnaptysBio vs. peers: Receivables Comparison

Loading

AnaptysBio Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AnaptysBio (ANAB) FAQ

The latest receivables for ANAB is $26M as of March 2026. That compares with $18M in the prior-year period — up 44.0% year over year. Investors often review this figure alongside AnaptysBio's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANAB's receivables moved from $18M to $26M — a 44.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AnaptysBio's operating scale or balance-sheet position.

A receivables figure of $26M for ANAB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ANAB's receivables ($26M), review year-over-year change from $18M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack AnaptysBio's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.